Stille

Stille Equity Growth

The Year-over-Year Equity Growth of Stille (STIL.ST) as of Oct 24, 2026 is 1.33 %. In the previous year, Year-over-Year Equity Growth was 10.62 % — a change of -87.47% (lower).

Equity Growth

1.33 %

YoY

-87.47%

Last updated:

Year-over-Year Equity Growth of Stille is 2025 1.33 % . Year-over-Year Equity Growth of Stille was 2024 10.62 % . It decreases by -87.47% lower compared to the previous year.

The Stille Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
20.92 SEK
Jan 1, 2019
19.66 SEK
Jan 1, 2020
7.79 SEK
Jan 1, 2021
33.37 SEK
Jan 1, 2022
28.16 SEK
Jan 1, 2023
233.09 SEK
Jan 1, 2024
10.62 SEK
Jan 1, 2025
1.33 SEK
The Stille Equity Growth history
YEAREquity GrowthYoY
1.33 %-87.47%
10.62 %-95.44%
233.09 %+727.64%
28.16 %-15.60%
33.37 %+328.46%
7.79 %-60.37%
19.66 %-6.02%
20.92 %+46.80%
14.25 %-47.69%
27.23 %-0.61%
27.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

Year-over-Year Equity Growth of Stille is 1.33 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Stille since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Stille historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Stille

All Key Metrics — Stille